Hims & Hers Health, Inc. (NYSE:HIMS) Receives $30.46 Consensus Target Price from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has received an average rating of “Hold” from the seventeen analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $30.75.

HIMS has been the subject of several recent research reports. Evercore set a $24.00 target price on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. Bank of America upgraded Hims & Hers Health from an “underperform” rating to a “neutral” rating and raised their target price for the stock from $12.50 to $23.00 in a research note on Tuesday. Finally, BTIG Research lowered Hims & Hers Health from a “buy” rating to a “neutral” rating in a report on Tuesday, February 24th.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Novo Nordisk pact ends lawsuit and establishes a commercial pathway for Ozempic and Wegovy on Hims’ platform — the agreement removes a major legal overhang and directly boosts revenue and credibility expectations. Hims shares notch record week as Novo pact spurs optimism
• Positive Sentiment: Several broker notes and price‑target/upside forecasts have followed the Novo news, including bullish coverage that highlights strong upside potential and helped drive volume. Barclays Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock
• Positive Sentiment: Pre‑market and intraday rallies (big volume spikes) reflected momentum traders buying the Novo settlement and analyst upgrades. Hims & Hers Health shares rally continues, up 7% in premarket Thursday
• Neutral Sentiment: Bank of America moved its coverage (raised to Neutral), and other firms are re‑rating the stock; analyst interest increases liquidity but opinions differ on valuation and risks. Hims & Hers Health (NYSE:HIMS) Raised to Neutral at Bank of America
• Neutral Sentiment: Corporate hires (communications leader) and company messaging improvements aim to steady the narrative as the Novo story evolves — helps investor relations but not an immediate earnings driver. Hims & Hers Adds Communications Leader As Expansion And Novo Story Evolve
• Negative Sentiment: Regulatory and margin pressures remain a material risk: FDA crackdown on compounded GLP‑1 formulations, prior warning letters and potential enforcement actions have pressured sentiment and valuation. Is Hims & Hers Really the Growth Stock to Buy That It Appears?
• Negative Sentiment: Shares have been down sharply over recent months and saw volatility around company headlines; some outlets flagged a ~29% three‑month decline and one‑day drops that reflect lingering execution and margin concerns. Hims & Hers Plunges 29.4% in Three Months: How to Play the Stock?
• Negative Sentiment: Short‑term pullbacks (including a recent ~7.9% one‑day drop) show that headline risk still drives outsized moves; investors should weigh upside from the Novo deal against execution, regulatory and margin risks. Here’s Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $24.74 on Wednesday. The company has a market capitalization of $5.64 billion, a P/E ratio of 48.51, a P/E/G ratio of 2.26 and a beta of 2.55. The business has a fifty day simple moving average of $23.84 and a two-hundred day simple moving average of $37.44. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same quarter in the prior year, the company earned $0.11 EPS. The firm’s quarterly revenue was up 28.4% compared to the same quarter last year. On average, analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has approved a stock buyback plan on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Transactions at Hims & Hers Health

In related news, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the sale, the insider owned 6,175 shares in the company, valued at approximately $226,684.25. This trade represents a 53.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Oluyemi Okupe sold 23,090 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $35.72, for a total value of $824,774.80. Following the transaction, the chief financial officer owned 94,333 shares of the company’s stock, valued at approximately $3,369,574.76. The trade was a 19.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 80,463 shares of company stock valued at $2,846,696. Corporate insiders own 13.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently made changes to their positions in the stock. Quent Capital LLC bought a new stake in shares of Hims & Hers Health during the 3rd quarter worth $28,000. Binnacle Investments Inc bought a new position in Hims & Hers Health in the third quarter valued at $28,000. Virtus Advisers LLC purchased a new stake in Hims & Hers Health during the second quarter valued at about $26,000. Hilltop National Bank purchased a new stake in Hims & Hers Health during the third quarter valued at about $35,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its stake in Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock worth $37,000 after purchasing an additional 600 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.